Manuel Baca Cots
Overview
Explore the profile of Manuel Baca Cots including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dagan R, Hammitt L, Nunez B, Baca Cots M, Bosheva M, Madhi S, et al.
J Pediatric Infect Dis Soc
. 2024 Jan;
13(2):144-147.
PMID: 38219024
To characterize nirsevimab in the prevention of RSV, children from the Phase 3 MELODY trial were followed through their second RSV season. No increase in medically attended RSV lower respiratory...
2.
Muller W, Madhi S, Nunez B, Baca Cots M, Bosheva M, Dagan R, et al.
N Engl J Med
. 2023 Apr;
388(16):1533-1534.
PMID: 37018470
No abstract available.
3.
Simoes E, Madhi S, Muller W, Atanasova V, Bosheva M, Cabanas F, et al.
Lancet Child Adolesc Health
. 2023 Jan;
7(3):180-189.
PMID: 36634694
Background: In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants born preterm or at...
4.
Hammitt L, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi S, et al.
N Engl J Med
. 2022 Mar;
386(9):837-846.
PMID: 35235726
Background: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has...